DOW

Dow Inc. is one of the world's largest commodity-to-specialty materials science companies and the largest chemical producer in North America by scale. Its economic engine is a globally integrated, feedstock-advantaged ethylene and propylene chain — anchored on the U.S. Gulf Coast and Western Canada — that converts low-cost natural-gas liquids into polyethylene, ethylene oxide derivatives, polyurethane intermediates, acrylics and silicones sold into packaging, infrastructure, mobility, consumer and industrial markets. Roughly half of revenue comes from Packaging & Specialty Plastics, making Dow's earnings highly levered to the global polyethylene margin cycle. After an extended 2023–2025 downcycle that drove a GAAP net loss of $2.4 billion in FY2025, a 50% dividend cut, three credit-rating downgrades and an AI-enabled restructuring ("Transform to Outperform"), Dow's 2026 earnings have rebounded sharply on Middle East supply disruption and self-help. A new CEO, Karen S. Carter, took over on 1 July 2026 to execute the turnaround.

Company's own description

In its FY2025 10-K and press-release boilerplate, Dow describes itself as one of the world's leading materials science companies serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications, operating manufacturing sites in 29 countries, employing ~34,600 people and generating ~$40 billion of 2025 sales. It frames its competitive edge around global breadth, asset integration and scale, focused innovation, and leading business positions.

What Dow actually does — independent characterization

Dow is fundamentally a vertically integrated petrochemical converter. It cracks ethane, propane and naphtha into ethylene and propylene (and co-products), then upgrades most of that molecule stream internally rather than selling it as merchant olefins. The integrated chain looks like this:

1. Feedstocks & energy (Hydrocarbons & Energy business): natural-gas liquids and naphtha purchased on index pricing; crackers in Freeport (TX), Plaquemine and St. Charles (LA), Fort Saskatchewan (AB), Terneuzen (NL), Böhlen (DE, slated for closure), Tarragona (ES), Bahía Blanca (AR), plus equity crackers via joint ventures (Sadara in Saudi Arabia, Thai JVs with SCG, Kuwait JVs).

2. First-derivative conversion: polyethylene (Dow is the world's leading PE producer by company claim), ethylene oxide/glycol, propylene oxide/glycol, chlor-alkali and vinyl (Europe, being rationalized), acrylic monomers, siloxanes.

3. Downstream formulated/specialty products: polyurethane systems, acrylic emulsions for coatings, silicone elastomers/fluids/resins, surfactants, amines, cellulose ethers, specialty elastomers and packaging resins.

Business model and revenue model

Product sales dominate (~98% of revenue): Revenue is overwhelmingly product sales under spot, contract (often formula-priced against feedstock/benchmarks) and long-term supply agreements. Q4 FY2025 cash flow references "advance payments received for low-carbon solutions and other long-term supply agreements," indicating a growing contracted component.

Technology licensing (~1–2%): Dow licenses process technology (e.g., UNIPOL™ polyethylene process via Univation-heritage licensing, METEOR™ EO/EG process) and catalysts.

Insurance operations (Corporate segment): Dow's captive insurance operations generated $701M of "Corporate" net sales in FY2025 (FY2024: $745M).

No meaningful subscription or service revenue: ### Value chain position

Upstream-to-midstream chemicals: Dow sits between oil & gas/NGL producers and converters/brand owners (film makers, packaging converters, paint formulators, foam producers, cable makers, personal-care formulators). It is a price-taker on feedstock and largely a price-taker on commodity polymers, with partial pricing power in specialties (silicones, acrylic binders, specialty elastomers).

Customer types and end-markets

Customers include flexible and rigid packaging converters, consumer packaged goods firms (directly and via converters), building & construction products manufacturers, paint and coatings formulators, automotive OEMs and Tier 1s, wire & cable manufacturers, appliance makers, personal-care and home-care formulators, pharma and food ingredient makers, energy/oilfield and industrial users, and electronics/semiconductor packaging firms (AI/advanced packaging materials showcased at SEMICON Taiwan, Sept 2026). End-markets by Dow's framing: packaging, infrastructure (building & construction, wire & cable, pipe), mobility (automotive, transportation), consumer (personal care, home care, electronics), industrial and energy.

Stated strategy themes (paraphrased from FY2025 10-K, earnings calls and conference presentations)

1. Lead through the cycle with low-cost, integrated assets — prioritize advantaged U.S. Gulf Coast and Canadian assets; rationalize high-cost European upstream capacity.

2. Decarbonize and grow — Path2Zero (deferred), low-carbon and circular product offerings with long-term supply agreements.

3. Self-help and productivity — cost programs, Transform to Outperform, AI/automation-led operating model.

4. Disciplined, balanced capital allocation — protect investment-grade ratings, deleverage, sustain a reset dividend, keep capex near D&A.

5. Customer-centric innovation — higher-value applications in packaging, infrastructure (wire & cable, pipe), mobility, consumer, electronics.

Strategic initiatives — last 24 months

Medium-term targets / guidance

Q3 FY2026 Operating EBITDA: $1.5–1.6bn (updated 16 Sep 2026), down from initial ~$1.7bn (23 Jul 2026). Segment guide at July: P&SP ~$1.2bn EBITDA; PM&C ~$300M.

Operating rates: >90% after Q3 planned maintenance.

Transform to Outperform: ≥$2bn EBITDA uplift (run-rate by 2028); >$200M EBITDA uplift from role reductions in 2H FY2026.

Capital allocation: debt reduction is first priority for excess cash; ~$14bn total available liquidity maintained.

Brand names are Dow trademarks (™). Launch years and pricing are generally not publicly disclosed; Dow sells on negotiated contract/spot terms referenced to industry benchmarks.

Packaging & Specialty Plastics

Industrial Intermediates & Infrastructure

Performance Materials & Coatings

Services

• Technology licensing and catalyst sales (P&SP, II&I).

• Technical service, application development and Pack Studios™ (packaging application centres)†.

• Captive insurance (Corporate).

Income statement — sources: 10-K FY2021–FY2025; FY2025 and FY2024 figures confirmed via Q4 FY2025 8-K exhibit

FY2025 operating EPS is the sum of quarterly operating EPS ($0.02, -$0.42, -$0.19, -$0.34). FY2025 dividends per share reflect two $0.70 and two $0.35 quarterly payments following the July 2025 cut.

Margins (%)

Revenue CAGR FY2021–FY2025: -7.7% per annum (USD 54,968M → 39,968M). FY2023–FY2025 CAGR: -5.4%.

Balance sheet

Balance-sheet lines sourced from 10-K data as compiled by StockAnalysis (short-term debt = notes payable + LTD due within one year); equity derived as total assets less total liabilities. Dow's own non-GAAP net debt definition (gross debt less cash and marketable securities) was $13,960M at 31 Dec 2025 and $13,615M at 31 Mar 2026 (10-Q Q1 FY2026). Goodwill was partly impaired in FY2025 (restructuring, goodwill impairment and asset-related charges totalled $1,856M in FY2025 vs $103M in FY2024).

Latest balance sheet (30 Jun 2026, 10-Q Q2 FY2026): total assets $61,585M; cash & equivalents $3,973M; long-term debt $17,151M; LTD due within one year $758M; notes payable $86M; total equity $17,367M (incl. NCI); cash plus committed and available liquidity $13.5bn; committed credit facilities $8.2bn undrawn; no commercial paper outstanding.

Cash flow

FY2025 CFO derived from quarterly releases (Q1 $104M, Q2 -$470M, Q3 ~$1,130M, Q4 $298M); company states ~$1.1bn. FY2025 dividends paid = sum of quarterly "returns to shareholders" ($496M + $496M + $249M + $251M).

1H FY2026 snapshot (unaudited): net sales $21,886M; Operating EBIT $1,802M; Operating EBITDA $3,185M; net income $357M; GAAP EPS $0.25. Q1 FY2026 CFO $1.1bn (boosted by the ~$1.3bn NOVA receipt) with free cash flow of $621M; Q2 FY2026 CFO $1,324M. Dividends paid ~$252M (Q1) and $253M (Q2). No buybacks.

Ratios

Using Dow-defined net debt ($13,960M) the FY2025 leverage was 4.3x. Moody's measured adjusted net debt/EBITDA at 5.2x as early as March 2025 (vs 1.9x end-2022). 1H FY2026 Operating EBIT of $1,802M against interest expense of $429M implies ~4.2x coverage, versus well under 1x in FY2025.

Commentary — trends, inflections and drivers

Revenue. Sales peaked in FY2022 ($56.9bn) as post-COVID restocking and energy-driven pricing lifted polyolefins and intermediates. FY2023 fell 21.6% as prices normalized and customers destocked; FY2024 and FY2025 declined a further 3.7% and 7.0% almost entirely on price (FY2025 local price -7%, volume flat), reflecting a structural global ethylene/polyethylene capacity overhang driven by Chinese additions and weak construction, durable-goods and European industrial demand.

Profitability. Operating EBITDA held ~$5.4–5.5bn in FY2023–FY2024 because cost cuts and Gulf Coast cost advantage offset price declines, but collapsed to $3.3bn in FY2025 as integrated margins compressed, equity affiliates (Sadara, Thai JVs) swung to losses, and European assets ran at low rates. GAAP results were further depressed by $1.86bn of restructuring, goodwill impairment and asset charges, Sadara guarantee adjustments and tax items, producing a $2.6bn attributable loss.

FY2026 inflection. The Q2 FY2026 swing to $2.3bn of quarterly Operating EBITDA and $802M of GAAP net income was driven by a ~20% local-price increase (P&SP +30%), triggered by the 2026 Middle East conflict and Strait of Hormuz disruption that removed Gulf supply, plus >$300M of quarterly self-help. Management guided Q3 FY2026 EBITDA initially to ~$1.7bn and later to $1.5–1.6bn as June polyethylene price settlements fed through, implying the Q2 peak was partly a price spike rather than a durable reset.

Balance sheet & cash. Net debt rose ~$2.3bn between FY2023 and FY2025 while the company continued to pay a $2.80 dividend through mid-2025 and spend ~$3bn/year of capex, which rating agencies cited as a governance concern. Mitigants included the $2.4bn (plus 9% follow-on) Diamond Infrastructure stake sale, the ~$1.3bn NOVA receipt in March 2026, the dividend halving and the Path2Zero delay. Management's stated priority (Q2 FY2026 call) is repaying the ~$1bn+ of debt added over the prior 12 months.

Management guidance (latest)

Q3 FY2026 Operating EBITDA: $1.5–1.6bn (16 Sep 2026), down from ~$1.7bn guided on 23 Jul 2026, reflecting early-quarter PE price declines, heavy cracker/PDH turnarounds, seasonal coatings and construction softness and European price pressure; partially offset by stronger September order books (including Asia) and a 10–12 cents/lb Americas PE price initiative.

Self-help: >$1.3bn in-year benefit for FY2026; >$200M EBITDA uplift from role reductions in 2H FY2026; ~$60M from the Barry closure in 2H FY2026.

Transform to Outperform: ≥$2bn EBITDA uplift with run-rate by 2028.

Capital allocation: debt reduction first; ~$14bn liquidity maintained.

Bull case

1. Structurally lower cost base: if Transform to Outperform delivers ≥$2bn and prior programs deliver ≥$1bn, mid-cycle EBITDA could rise materially above the ~$5.4–5.5bn FY2023–FY2024 level even without price help.

2. Supply discipline: Middle East disruption plus European closures (including Dow's own Böhlen/Schkopau/Barry) remove capacity, and Dow's Gulf Coast cost position captures export share — as shown by Q2 FY2026 P&SP margins of ~20%.

3. Balance-sheet repair and rerating: NOVA proceeds, infrastructure monetization and higher cash flow (Q2 FY2026 CFO $1.3bn) support deleveraging; at ~7x TTM EBITDA and a ~5% yield, stabilizing ratings could rerate the shares.

Bear case

1. 2026 was a price spike, not a recovery: Q3 guidance has already been cut twice from the $2.3bn Q2 run-rate; normalization of Gulf exports and Chinese capacity additions could return margins toward FY2025 levels.

2. Leverage and ratings: S&P sits at BBB- with a negative outlook; any relapse in earnings risks a fall to high-yield at one agency, raising funding costs on a ~$17bn debt stack.

3. Execution and contingent liabilities: cutting ~13% of the workforce during a CEO transition raises operational-safety and reliability risk, while Sadara guarantees, asbestos and indemnification charges continue to drain cash; the NOVA appeal could theoretically claw back proceeds.

Catalysts and monitorables (next 12 months)

• Q3 FY2026 results (22 Oct 2026) — delivery versus the $1.5–1.6bn EBITDA guide and Q4 outlook.

• Middle East / Strait of Hormuz developments and resulting PE price settlements (Americas initiatives Sept–Oct 2026).

• Transform to Outperform milestones (near-complete role reductions by year-end 2026) and FY2027 savings bridge.

• Credit-rating agency reviews (especially S&P's negative outlook at BBB-).

• Canadian tax withholding refund on NOVA proceeds (expected by year-end 2026) and status of NOVA's appeal.

• Sadara financing / restructuring decisions and guarantee exposure.

• European closure execution (Böhlen, Schkopau) and Terneuzen performance.

• FY2027 capex plan and Path2Zero spend cadence.

• Dividend declarations (next expected mid-October 2026).

• Any announced "portfolio reshaping" transactions (currently unconfirmed).

Analyst verdict

Dow enters Q4 2026 as a classic early-cycle restructuring story whose fundamentals have improved faster than its credit and equity profile. The evidence for operational improvement is concrete: Operating EBITDA swung from $703M in Q2 FY2025 to $2.3bn in Q2 FY2026; GAAP earnings turned positive; self-help is running ahead of plan at more than $1.3bn for the year; and liquidity remains ample at $13.5bn. The company has also addressed the governance criticism that drove its 2025 downgrades by halving the dividend, halting buybacks and monetizing infrastructure and litigation assets.

However, the quality of the 2026 earnings rebound is debatable. Most of the improvement came from a 20% price surge rooted in a geopolitical supply shock rather than demand recovery — volume actually fell in Q2 — and management has already lowered Q3 EBITDA guidance from ~$1.7bn to $1.5–1.6bn. Industry-wide ethylene oversupply, expected by Fitch to persist for five to six years, has not gone away. Leverage of roughly 4–5x on FY2025 EBITDA and a BBB-/negative S&P rating leave little margin for error if prices normalize before Transform to Outperform's ≥$2bn uplift fully lands in 2027–2028.

At ~$28.50, the shares trade at roughly 7x trailing Operating EBITDA, ~0.5x sales and ~1.3x book, with a ~5% yield — inexpensive versus history but not distressed, and the sell-side has turned more cautious (Citi downgrade, multiple target cuts in late September). Our synthesis is a neutral-to-constructive stance with a cyclical-recovery option: the downside is cushioned by self-help and liquidity, while upside depends on whether new CEO Karen Carter can convert a temporary pricing windfall into durable balance-sheet repair. The single most important monitorable is whether quarterly EBITDA can hold above ~$1.5bn as Middle East supply normalizes; if it can, a rating stabilization and rerating are plausible in 2027.

SOURCES (primary and secondary references used)

• Dow Inc. Form 10-K FY2025 (SEC EDGAR, CIK 1751788) and 2025 Annual Report — https://www.sec.gov/Archives/edgar/data/1751788/000175178826000018/dow-20251231.htm ; https://s23.q4cdn.com/981382065/files/doc_financials/2025/q4/DOW-INC-2025-10K-FINAL.pdf

• Dow Inc. Form 10-K FY2024 (filed 4 Feb 2025)

• Dow Inc. Form 10-Q Q1 FY2026 and Q2 FY2026 — https://www.sec.gov/Archives/edgar/data/0001751788/000175178826000134/dow-20260331.htm ; https://www.sec.gov/Archives/edgar/data/0001751788/000175178826000147/dow-20260630.htm

• Dow 8-K earnings exhibits: Q4 FY2024, Q2 FY2025, Q3 FY2025, Q4 FY2025, Q1 FY2026, Q2 FY2026 (sec.gov; investors.dow.com; corporate.dow.com)

• Dow Inc. DEF 14A filed 27 Feb 2026 — https://www.sec.gov/Archives/edgar/data/1751788/000119312526082583/dow-20260227.htm

• Dow 8-K, 14 Apr 2026 (CEO succession) — https://www.sec.gov/Archives/edgar/data/1751788/000119312526153769/d103960d8k.htm

• Dow 8-K, 3 Dec 2024 (COO appointment)

• Dow press release: NOVA payment, 3 Mar 2026 — corporate.dow.com

• Dow news page (Sep 2026 releases: Amcor, CPHI, SEMICON, Laguna) — https://corporate.dow.com/en-us/news.html

• Q1 and Q2 FY2026 earnings call transcripts (Investing.com, Yahoo Finance) and Morgan Stanley Laguna Conference transcript, 16 Sep 2026 (Investing.com; Chemical Week)

• Manufacturing Dive, PlasticsToday, The Register — Transform to Outperform coverage (Jan 2026)

• Alberta Industrial Heartland, Alberta Major Projects, EnergyNow — Path2Zero status (Jan–Feb 2026)

• Moody's (via Investing.com, Jul 2025); Fitch (via Investing.com, Jul 2025); S&P (via Cbonds, Feb 2026)

• Morningstar quote page for DOW (5 Oct 2026); StockAnalysis (dividends, balance sheet); TipRanks/CNN Markets (analyst actions, Sep 2026)

• CNBC market coverage (28–29 Sep 2026) for macro and Hormuz context

--